Becton, Dickinson and Company (BD) Insider Sale and Financial Overview

  • Shan David, Executive Vice President and Chief ISC Officer at BD, sold 1,166 shares at $171.19 each, signaling potential insights into the company's future performance.
  • BD issued an urgent update on its esophagogastric balloon tamponade tubes due to safety concerns, impacting its market performance.
  • The company's financial metrics, including a price-to-earnings (P/E) ratio of 32.61 and a debt-to-equity ratio of 0.76, provide a comprehensive view of its valuation and financial health.

Becton, Dickinson and Company, known as BD and trading under the symbol NYSE:BDX, is a global medical technology company. It specializes in the development and sale of medical devices, instrument systems, and reagents. BD's operations are divided into three segments: BD Medical, BD Life Sciences, and BD Interventional. The company faces competition from other medical technology firms like Medtronic and Johnson & Johnson.

On June 2, 2025, Shan David, Executive Vice President and Chief ISC Officer at BD, sold 1,166 shares of the company's common stock at $171.19 each. This transaction left him with 4,575 shares. Such insider transactions can sometimes signal the executive's perspective on the company's future performance. However, it's essential to consider other factors, such as personal financial planning, when interpreting these actions.

BD recently issued an urgent update regarding its esophagogastric balloon tamponade tubes, following reports of one death and two serious injuries. The FDA has highlighted BD's updated instructions to alert healthcare professionals to potential hazards. Despite this announcement, BD's stock traded flat until Thursday's close. However, the stock has experienced a 23.4% decline year-to-date, compared to the industry's 0.8% decrease.

BD's financial metrics provide insight into its valuation and performance. The company's price-to-earnings (P/E) ratio is approximately 32.61, indicating the price investors are willing to pay for each dollar of earnings. The price-to-sales ratio stands at about 2.33, reflecting the value placed on its revenue. Additionally, the enterprise value to sales ratio is around 3.22, suggesting the company's total valuation relative to its sales.

The enterprise value to operating cash flow ratio is approximately 20.36, highlighting BD's valuation in relation to its cash flow from operations. The earnings yield is about 3.07%, providing insight into the return on investment. The debt-to-equity ratio is approximately 0.76, indicating the proportion of debt used to finance the company's assets relative to shareholders' equity. Lastly, the current ratio is about 1.13, suggesting BD's ability to cover its short-term liabilities with its short-term assets.

Symbol Price %chg
7741.T 16580 -0.42
OMED.JK 180 1.11
4543.T 2518.5 -3.32
MARK.JK 650 0
BDX Ratings Summary
BDX Quant Ranking
Related Analysis

Becton, Dickinson and Company (BD) Surpasses Earnings and Revenue Estimates

  • Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year's $2.68.
  • Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 billion and indicating a 9.8% increase year-over-year.
  • Completion of a $750 million share repurchase in fiscal year 2025, reflecting confidence in BD's financial stability and future prospects.

Becton, Dickinson and Company, known as BD, trades on the NYSE:BDX. It is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD's competitors include companies like Medtronic and Johnson & Johnson. The company focuses on improving medical discovery, diagnostics, and the delivery of care.

On February 6, 2025, BD reported earnings per share (EPS) of $3.43, surpassing the estimated $3. This strong performance is further highlighted by the Zacks Consensus Estimate, which was $2.98 per share. Compared to the same quarter last year, where EPS was $2.68, BD shows significant growth, reflecting its robust financial health and operational efficiency.

BD's revenue for the first quarter of fiscal 2025 reached approximately $5.17 billion, exceeding the estimated $5.10 billion. The company achieved a 9.8% increase in revenue, with 9.6% being currency-neutral and 3.9% organic growth. This indicates BD's ability to grow its business despite currency fluctuations, showcasing its strong market position and strategic execution.

The company has also completed a $750 million share repurchase in fiscal year 2025, demonstrating confidence in its financial stability and future prospects. BD's price-to-earnings (P/E) ratio of 41.12 and price-to-sales ratio of 3.52 reflect the market's positive valuation of its earnings and sales. The enterprise value to sales ratio of 4.43 and enterprise value to operating cash flow ratio of 23.56 provide insight into BD's overall value and cash flow efficiency.

BD's strategic initiatives, such as the BD 2025 strategy, aim to unlock significant value through the planned separation of Biosciences and Diagnostic Solutions. This move is expected to allow each entity to focus on maximizing growth and innovation. With a debt-to-equity ratio of 0.35 and a current ratio of 1.17, BD maintains a moderate level of debt and a solid ability to cover short-term liabilities, ensuring financial stability.

Becton, Dickinson and Company (BD) Surpasses Earnings and Revenue Estimates

  • Earnings Per Share (EPS) of $3.43, beating the estimated $3 and showing significant growth from the previous year's $2.68.
  • Revenue reached approximately $5.17 billion, surpassing the estimated $5.10 billion and indicating a 9.8% increase year-over-year.
  • Completion of a $750 million share repurchase in fiscal year 2025, reflecting confidence in BD's financial stability and future prospects.

Becton, Dickinson and Company, known as BD, trades on the NYSE:BDX. It is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD's competitors include companies like Medtronic and Johnson & Johnson. The company focuses on improving medical discovery, diagnostics, and the delivery of care.

On February 6, 2025, BD reported earnings per share (EPS) of $3.43, surpassing the estimated $3. This strong performance is further highlighted by the Zacks Consensus Estimate, which was $2.98 per share. Compared to the same quarter last year, where EPS was $2.68, BD shows significant growth, reflecting its robust financial health and operational efficiency.

BD's revenue for the first quarter of fiscal 2025 reached approximately $5.17 billion, exceeding the estimated $5.10 billion. The company achieved a 9.8% increase in revenue, with 9.6% being currency-neutral and 3.9% organic growth. This indicates BD's ability to grow its business despite currency fluctuations, showcasing its strong market position and strategic execution.

The company has also completed a $750 million share repurchase in fiscal year 2025, demonstrating confidence in its financial stability and future prospects. BD's price-to-earnings (P/E) ratio of 41.12 and price-to-sales ratio of 3.52 reflect the market's positive valuation of its earnings and sales. The enterprise value to sales ratio of 4.43 and enterprise value to operating cash flow ratio of 23.56 provide insight into BD's overall value and cash flow efficiency.

BD's strategic initiatives, such as the BD 2025 strategy, aim to unlock significant value through the planned separation of Biosciences and Diagnostic Solutions. This move is expected to allow each entity to focus on maximizing growth and innovation. With a debt-to-equity ratio of 0.35 and a current ratio of 1.17, BD maintains a moderate level of debt and a solid ability to cover short-term liabilities, ensuring financial stability.